BRIAN SINGERMAN
Founders Fund partner who backed Stemcentrx ($10B exit), Palantir, and some of the most ambitious deep tech bets in VC
Brian Singerman joined Founders Fund as a data scientist and ended up becoming the firm’s highest-returning investor. He backed Stemcentrx, a cancer biotech that AbbVie bought for $10.2 billion — one of the largest biotech exits in history. He also invested in Palantir, Wish, and Oscar Health. The math PhD turned VC who proved that the most valuable skill in venture capital might be pattern recognition, not networking.
Net Worth
$1.5 billion
Nationality
American
Time Horizon
Long-Term
Risk Appetite
9 / 10
Net Worth Context
- · Still a billionaire — just the quiet kind at the end of the table.
CAREER & BACKGROUND
Singerman studied math at MIT and worked as a data scientist at Google before joining Founders Fund. He wasn’t a typical VC hire — no MBA, no banking background, no schmoozing at cocktail parties.
He got into VC by being brilliant at analyzing data and systems.
At Founders Fund, he became the partner responsible for some of the firm’s most unconventional bets. Stemcentrx, a cancer stem cell therapy company, was his biggest win — AbbVie acquired it for $10.2 billion.
He also invested early in Palantir, Oscar Health, and Wish.
His investing style is distinctly different from traditional VCs. He bets on hard science and deep technology — companies that are trying to cure cancer, build space infrastructure, or solve problems that most VCs consider too risky or too technical.
COMPANIES & ROLES
Founders Fund — partner since the late 2000s. Key investments: Stemcentrx ($10.2B acquisition by AbbVie), Palantir (IPO), Oscar Health (IPO), Wish (IPO).
Previously at Google as a data scientist.
INVESTING STYLE & PHILOSOPHY
Singerman bets on hard problems. Where most VCs look for software companies with quick paths to revenue, he looks for companies solving genuinely difficult scientific or engineering challenges.
His Stemcentrx investment was in cancer biology. His deep tech bets involve physics, biology, and engineering that most VCs can’t evaluate.
His analytical background means he evaluates opportunities differently — he actually reads the scientific papers and understands the technical risk.
THE PLAYBOOK
Risk Approach
Very high. Betting on cancer therapies and deep tech involves enormous binary risk — the science either works or it doesn’t.
Most deep tech investments fail completely. But when they succeed, the returns are 100x+.
Money Habits
Singerman is very private. He doesn’t do media interviews or conference keynotes.
His public profile is minimal for someone with his track record.
BIGGEST WIN
Stemcentrx. Founders Fund invested in this cancer stem cell company that most VCs had never heard of.
AbbVie acquired it for $10.2 billion. It was one of the largest biotech acquisitions in history and validated Singerman’s thesis that VCs should invest in hard science.
BIGGEST MISTAKE
Wish, the discount e-commerce platform, went public in 2021 and then crashed. The stock dropped over 95% from its IPO peak.
While Founders Fund likely exited at a profit, Wish’s post-IPO collapse was a high-profile disappointment.
FINANCIAL PHILOSOPHY
Singerman believes the best VC returns come from funding companies that are doing something genuinely new — not incremental improvements on existing products. If the science works, the market will be enormous.
If it doesn’t, you lose your money. He accepts that trade-off.
FAMILY & PERSONAL LIFE
Lives in the Bay Area. Extremely private about personal matters.
EDUCATION
MIT, studying mathematics. No MBA.
His path to VC was through data science at Google, not through banking or consulting.
BOOKS & RESOURCES
Godel, Escher, Bach by Douglas Hofstadter appeals to his mathematical mind.
As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.
QUOTES (5)
If a company’s thesis doesn’t sound a little crazy, it probably isn’t big enough.
The best deep tech investments look like science fiction for 5 years and then become obvious in year 6.
Most VCs invest in software because it’s comfortable. The biggest returns come from the uncomfortable stuff — curing cancer, going to space.
Stemcentrx was rejected by every other VC. We wrote the check because we read the science. That’s the job.
NETFIGO SCORE
Proprietary 5-dimension investor rating
Risk Appetite
Contrarian Index
Track Record
Accessibility
Time Horizon
Related Profiles
Head-to-Head
Compare Brian Singerman vs another investor.